NAPP Logo
  • NAPP logo
  • About Us
  • Products
  • Working at Napp
  • Partnering
    • Commercial partnering
    • Joint working
  • Education
    • NAPP Academy
  • Media
    • News
    • Press Releases
  • Contact
  • Home
  • About Us
  • Products
  • Working at Napp
  • Partnering
  • Education
  • Media
  • Contact
Napp > Asthma device, k-haler®, celebrates two A’ Design Award & Competition wins

Asthma device, k-haler®, celebrates two A’ Design Award & Competition wins

  • April 25, 2018
Image for Asthma device, k-haler®, celebrates two  A’ Design Award & Competition wins

CAMBRIDGE, 25 April 2018 – The prestigious A’ Design Award, a competition which celebrates the world’s leading designs, concepts and design-orientated products, has awarded the k-haler® device two awards. The k-haler® device – which will be marketed in the UK by Napp Pharmaceuticals Ltd when it launches later this year – received platinum awards for its innovative design in the “Scientific Instruments, Medical Devices and Research Equipment Design” and “Ease of Use and Universal Design” categories, impressing the jury panel of 212 design professionals, press members and academics. This year, the competition attracted entries from across 100 countries.

 

The k-haler® device is a novel aerosol device with a simple breath-actuated mechanism, activated with a low inspiratory force. The device and packaging were designed with the patient and clinician in mind, aimed at helping to address some of the day-to-day challenges faced by patients using an inhaler, and to improve correct device usage.

 

Ross Grey, Napp’s Director of Primary Care commented that “we’re delighted that the k-haler® device has been recognised for its innovative design, which is testament to the research and development that went into the device. At Napp, we want to add value to the NHS through more than products, and the k-haler® does precisely this. Our aim with the k-haler® is to help patients use their asthma device correctly, thereby hopefully improving their long-term outcomes whilst helping the NHS deliver high-quality and sustainable healthcare.”

 

Research indicates that errors in inhaler technique are frequent (made by over 30% of patients in some cases) and are associated with poor outcomes.[i] Evidence suggests that inhaler type and patient preference are important factors influencing treatment outcomes in patients.[ii] Furthermore, ongoing training may also influence the efficiency of drug delivery, patient adherence and long-term control.[iii] Research has also demonstrated that simple techniques, such as attaching instruction labels to patients’ inhalers, have been shown to improve retention of good inhaler technique.[iv]

 

Earlier this year, the k-haler® device won an iF DESIGN AWARD, triumphing in the “Packaging Design” discipline of the “Medicine / Pharmaceutics” category, and was recognised for its innovative patient information packaging and online training tools.[v] Napp hopes that with its award-winning device and packaging, k-haler® will help improve correct device usage in patients with respiratory disease.

 

k-haler® received a positive outcome from the European Decentralised Procedure (DCP) in October 2017, and is planned to launch in the UK later this year. The k-haler® device’s patented technology has the potential to be suitable for a range of inhaled products.

 

-Ends-

 

Notes to editors

About Napp Pharmaceuticals Ltd

Napp Pharmaceuticals Ltd is a UK pharmaceutical company based in the heart of the Cambridge science community, and part of a worldwide network of independently associated companies across 48 countries. Napp has grown up with the NHS, providing innovative medicines to patients in the UK since the 1920s. Napp is committed to improving patient outcomes and ensuring the sustainability of healthcare. At Napp, we are proud of our heritage, which began in the treatment of chronic pain and has expanded into respiratory medicine, oncology and inflammatory disorders. For more information, please visit www.napp.co.uk

 

About the k-haler® device

k-haler® is a novel aerosol device with a unique breath-actuated mechanism, utilising a patented ‘kinked’ valve – the k-valveTM.  The inhaler, which is activated with a low inspiratory force, is designed with the aim to make it easier for patients to use correctly.

 

About the A’ Design Award & Competition

For the last nine years, the A’ Design Award & Competition has highlighted the excellent qualifications of best designs, design concepts and design-oriented products worldwide in all creative disciplines and industries. Submissions across 110 categories from aerospace to architecture to medical devices are judged by a 212-strong International Design Academy – The Grand A’ Design Award Jury Panel – composed of design professionals, press members and academics. For more information, please visit: https://competition.adesignaward.com/index.html.

 

® K-HALER is a registered trademark of Mundipharma.

    K-VALVETM is a trademark of Mundipharma

 

References

[i] D.Price et al. “Inhaler errors in the CRITIKAL Study: type, frequency and association with asthma outcomes”. Journal of Allergy and Clinical Immunology: In Practice. 2017 DOI: http://dx.doi.org/10.1016/j.jaip.2017.01.004

[ii] Haughney J, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102:1681–93

[iii] GINA. Global Strategy for Asthma Management and Prevention. 2017.

[iv] Basheti IA et al. NPJ Prim Care Respir Med 2017;27:9.

[v] iF DESIGN AWARDS 2018 https://ifworlddesignguide.com/search?search=k-haler#/page/entry/232843-k-haler/

Stay connected

  • Legal
  • Cookie Policy
  • Privacy Notice
  • Registered Company
  • Modern Slavery Statement
  • Integrity Line
  • Tax Strategy
  • Group Pension Scheme
  • PENSION IMPLEMENTATION STATEMENT
  • Statement of Investment Principles
© 2022 NAPP Pharmaceuticals Limited. Last updated: May 2019

You are now leaving our website. Napp does not accept any responsibility for the third party site.

Please click "Continue to external link" if you want to proceed.

Go Back
Continue to external link

This website uses cookies so that we can provide you with the best user experience possible.

 

Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

 

We use necessary cookies to ensure the proper functioning of our site.

 

We'd also like to set optional analytics cookies to help us to improve your experience when using the site. We won't set optional cookies unless you choose to enable them. Using this tool will place a cookie on your device which will remember your preferences when you next visit.

 

For more detailed information about the cookies we use, please refer to our Cookie Policy. Settings.

Napp
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy